Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic AAV8-SIL1-TAT therapy improves motor function in a mouse model of Marinesco-Sjögren syndrome.

Biochemical pharmacology·2026
Same author

Tumor microenvironment remodeling by STING agonism sensitizes endothelial cells to cytotoxic anti-PD-L1/L2 antibody.

Journal of experimental & clinical cancer research : CR·2026
Same author

From image to insight: optimized multiplex staining panel for formalin-fixed, paraffin-embedded mouse bone marrow enables spatial profiling of the hematopoietic niche.

Experimental hematology·2026
Same author

Feasibility Study of Decellularized Corneal Lenticule in a Porcine Model for Macular Hole Closure.

Ophthalmology and therapy·2026
Same author

Multiparametric staining - combined application of immunofluorescence and in-situ hybridization.

Methods in cell biology·2026
Same author

Extracellular matrix and morphology assessment method on live 3D spheroids of thyroid carcinoma.

Methods in cell biology·2026

Related Experiment Video

Updated: May 8, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

HER-2/neu mediates oncogenic transformation via altered CREB expression and function.

André Steven1, Sandra Leisz, Chiara Massa

  • 1Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Magdeburger Str. 2, 06112 Halle, Germany. Barbara.Seliger@uk-halle.de.

Molecular Cancer Research : MCR
|September 13, 2013
PubMed
Summary

Cyclic (c)AMP responsive element binding protein (CREB) drives HER-2/neu-mediated transformation, impacting tumor growth and immune response. Inhibiting CREB reduces tumor cell proliferation and migration, suggesting CREB as a potential cancer therapy target.

More Related Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

Related Experiment Videos

Last Updated: May 8, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Signaling

Background:

  • Cyclic (c)AMP responsive element binding protein (CREB) is crucial for cellular processes and implicated in tumorigenesis.
  • HER-2/neu overexpression is linked to various cancers, but its mechanistic link to CREB remains unclear.

Purpose of the Study:

  • To investigate the mechanistic link between HER-2/neu-mediated transformation and CREB expression and function.
  • To evaluate the role of CREB in HER-2/neu-driven tumor growth, metastasis, and immunogenicity.

Main Methods:

  • Utilized in vitro models of HER-2/neu-overexpressing and silenced cells, alongside human mammary carcinoma samples.
  • Employed shRNA-mediated inhibition of HER-2/neu and CREB, chemical inhibitors (KG-501, lapatinib), and in vivo xenograft models.
  • Assessed cell proliferation, cell-cycle arrest, migration, invasion, apoptosis, and tumor growth.

Main Results:

  • HER-2/neu overexpression induced CREB activation, while HER-2/neu inhibition downregulated CREB.
  • CREB downregulation in HER-2/neu-transformed cells reduced proliferation, migration, and invasion, causing cell-cycle arrest and increased fibronectin adherence.
  • In vivo, CREB inhibition significantly decreased tumor growth, enhanced apoptosis, and modulated immune cell infiltration.

Conclusions:

  • CREB is integral to HER-2/neu-mediated transformation, influencing tumor growth and characteristics.
  • CREB modulation impacts tumor immunogenicity, highlighting its potential as a therapeutic target in HER-2/neu-driven cancers.